These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29590134)

  • 21. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis.
    Girouard N; Théorêt G
    Can J Neurosci Nurs; 2008; 30(4):18-25. PubMed ID: 19146204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Teaching intramuscular self-injection in patients with multiple sclerosis reaching interferon beta-1a: evaluation of a descriptive multicenter program].
    Visy JM; Gentin M; Bazerque C;
    Presse Med; 2007 Jun; 36(6 Pt 1):841-50. PubMed ID: 17482792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon beta for multiple sclerosis.
    Connelly JF
    Ann Pharmacother; 1994 May; 28(5):610-6. PubMed ID: 8069001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
    Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
    J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advancing treatment with interferon beta-1b (Betaferon/Betaseron) in the next decade--thinking beyond the standard dose.
    Cook SD
    J Neurol; 2003 Dec; 250 Suppl 4():IV15-20. PubMed ID: 14712397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.
    Cristiano E
    Int J Clin Pract Suppl; 2002 Sep; (131):3-7. PubMed ID: 12564806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment.
    Hawken N; Torvinen S; Neine ME; Amri I; Toumi M; Aballéa S; Plich A; Roche N
    BMC Pulm Med; 2017 Jul; 17(1):99. PubMed ID: 28683805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calculating Preference Weights for the Labor and Delivery Index: A Discrete Choice Experiment on Women's Birth Experiences.
    Gärtner FR; de Bekker-Grob EW; Stiggelbout AM; Rijnders ME; Freeman LM; Middeldorp JM; Bloemenkamp KW; de Miranda E; van den Akker-van Marle ME
    Value Health; 2015 Sep; 18(6):856-64. PubMed ID: 26409614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS.
    Zivadinov R; Munschauer FE; Ramanathan M; Benedict RH; Weinstock-Guttman B
    Drugs Today (Barc); 2008 Aug; 44(8):601-13. PubMed ID: 18846271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.
    Durelli L
    J Neurol; 2003 Dec; 250 Suppl 4():IV9-IV14. PubMed ID: 14712396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany.
    Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Gleißner E; Mühlbacher A; Kieseier B
    Ther Adv Neurol Disord; 2016 Mar; 9(2):95-104. PubMed ID: 27006697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts.
    Castelli-Haley J; Oleen-Burkey MA; Lage MJ; Johnson K
    J Med Econ; 2010; 13(3):464-71. PubMed ID: 20662760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eliciting patients' preferences for epilepsy diagnostics: a discrete choice experiment.
    Wijnen BF; de Kinderen RJ; Colon AJ; Dirksen CD; Essers BA; Hiligsmann M; Leijten FS; Ossenblok PP; Evers SM
    Epilepsy Behav; 2014 Feb; 31():102-9. PubMed ID: 24389020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HLA class II and response to interferon-beta in multiple sclerosis.
    Fernández O; Fernández V; Mayorga C; Guerrero M; León A; Tamayo JA; Alonso A; Romero F; Leyva L; Alonso A; Luque G; de Ramón E
    Acta Neurol Scand; 2005 Dec; 112(6):391-4. PubMed ID: 16281922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.
    Bertolotto A; Sala A; Malucchi S; Marnetto F; Caldano M; Di Sapio A; Capobianco M; Gilli F
    J Neurol Neurosurg Psychiatry; 2004 Sep; 75(9):1294-9. PubMed ID: 15314118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conducting a Discrete-Choice Experiment Study Following Recommendations for Good Research Practices: An Application for Eliciting Patient Preferences for Diabetes Treatments.
    Janssen EM; Hauber AB; Bridges JFP
    Value Health; 2018 Jan; 21(1):59-68. PubMed ID: 29304942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.
    Basiri K; Etemadifar M; Derakhshan F; Ashtari F; Shaygannejad V; Fatehi Z; Maghzi AH; Fatehi F
    Acta Med Iran; 2012; 50(2):97-100. PubMed ID: 22359077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.